Real-World tracking begins for rare genetic disorder treatment
Disease control
ENROLLING_BY_INVITATION
This study is observing 200 patients with Prader-Willi syndrome who are taking the medication VYKAT XR. The main goal is to gather more information about the drug's safety and how patients respond during real-world use. It follows patients who are either starting the treatment or…
Sponsor: Soleno Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC